Press Releases

Creative Proteomics Launches Untargeted Metabolomics Services for Drug Development

Creative Enzymes Releases Biocatalysis Services for Process of Biocatalyst Development

Clinical Ink Announces Its Acquisition by GI Partners

Clinical Ink today announced its acquisition by GI Capital Partners, accelerating the momentum of the industry’s eSource leader.

Cinda Orr Named PharmaVOICE Top 100 Honoree

SCORR Marketing, the leading full-service marketing and communications firm in the health science industry, is proud to announce that the company’s CEO, Cinda Orr, has been included among PharmaVOICE Magazine’s 100 most inspiring individuals in the life sciences industry.

Panthera’s UK oncology clinical trial sites open for studies

Panthera's UK oncology clinical trial sites are open despite 1000+ international cancer trials being suspended due to COVID-19.

VantAI and TARA Biosystems Partner to Discover New Medicines

Over 300 Clinical Studies Benefit from CluePoints COVID-19 Risk Management Support

CluePoints, the premier provider of Risk-Based Study Execution (RBx) and Data Quality Oversight Software for clinical trials, today announced the success of its complimentary COVID-19 risk management package alongside comprehensive support for COVID-19 affected trials. Launched in April in the wake of COVID-19, the support package includes a widely used online Risk Assessment and Control solution that can be leveraged for performing risk planning and mitigation activities addressing inherent risks during this crisis.

Raremark® launches the Xperiome™ patient-powered knowledge platform to deliver new therapies faster and smarter

Raremark®, the leading online patient community in rare disease, has today launched its patient-powered knowledge platform Xperiome™ to help the pharmaceutical industry deliver innovative new therapies faster and smarter.

Notable Launches New Clinical Study With Washington University School of Medicine Exploring Ex Vivo Drug Screening to Predict Chemotherapy Sensitivity and Resistance

Notable announces a new precision oncology study with Washington University School of Medicine in St. Louis, exploring the feasibility of ex vivo drug screening to predict sensitivity and resistance to chemotherapy, and to identify novel synergies across a broad panel of anticancer therapies.

Phesi Powers Data-Driven Clinical Trials Through Addition of New Country Selection Functionality to ClinSite

AI-powered investigator site intelligence platform allows users to select top-performing investigators worldwide and save up to $2.4m per trial on non-performing sites

CD Genomics Announces Advanced CDAMP® Panel Kits for SARS-CoV-2 Detection

CD Genomics Launches Complete Product Portfolio for Research to COVID-19 Response

Cell-Based Solutions for Tumor Research Are Available by Creative Proteomics’s Tumomics Platform

Creative Proteomics Introduces Advanced Gut Metatranscriptome Analysis Solutions

Creative Enzymes Optimizes Screening of Enzyme Activators for Enzyme Profiling

IM Therapeutics Expands Management Team with Appointments of Tom Shea as CFO/COO and Dr. Sarah Bird as VP, Clinical Development

Creative Enzymes Optimizes Enzyme Stabilization and Formulation Services

Alfa Chemistry Testing Lab Provides Customized Pharmaceutical Analytical Services

Alfa Chemistry Testing Lab announced today that it has recently launched customized pharmaceutical analytical services for companies involved with new drug development.

CD Genomics Announces MicroCollect™ FDA&CE Certificated Virus Collection Swab Kits for SARS-CoV-2 Detection

FHI CLINICAL INC. PROVIDING CLINICAL OPERATIONS SERVICES FOR ACTT-1 TRIAL OF REMDESIVIR FOR TREATMENT OF COVID-19

FHI Clinical announced today a subcontract with the Frederick National Laboratory for Cancer Research, currently operated by Leidos Biomedical Research, Inc., to provide clinical operations services for the Adaptive COVID-19 Treatment Trial (ACTT). Supported by the NIAID, part of the NIH, the ongoing ACTT study is a randomized, double-blinded, placebo-controlled trial to allow investigation of putative therapeutics for the treatment of COVID-19 in hospitalized adults.